On that note, there exists a knowledge gap, and branching out across the ABC transporter family tree, such as ABCA1, ABCA13, ABCB9 and ABCD4 which carry negative prognostic values in GBM therapy evaluations using alkylating agents, might root out new discoveries. This evidence concerns the gene ABCD4 and glioblastoma.